Consolidated Statements Of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Jan. 29, 2023	Jan. 30, 2022	Jan. 31, 2021
Cash flows from operating activities:
Net income	$ 61,372	$ 125,645	$ 59,867
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	32,151	30,892	31,867
Amortization of right-of-use assets	4,742	4,410	3,991
Investment impairments and credit loss reserves, net	1,156	1,337	6,769
Accretion of deferred financing costs and debt discount	1,421	481	482
Deferred income taxes	(15,256)	(3,782)	(7,396)
Share-based compensation	39,248	51,189	52,986
Loss (gain) on disposition of business operations and assets	(18,260)	(54)	61
Changes in the fair value of contingent earn-out obligations	0	(13)	(33)
Equity in net (gains) losses of equity method investments	(249)	(2,115)	(329)
Corporate owned life insurance, net	810	4,766	6,508
Changes in assets and liabilities:
Accounts receivable, net	2,445	(1,074)	(8,506)
Inventories	(3,752)	(26,509)	(14,484)
Other assets	6,302	11,176	(15,069)
Accounts payable	(3,697)	(2,145)	3,565
Accrued liabilities	18,921	17,829	2,309
Other liabilities	(643)	(8,910)	(3,658)
Net cash provided by operating activities	126,711	203,123	118,930
Cash flows from investing activities:
Proceeds from sales of property, plant and equipment	38	110	385
Purchase of property, plant and equipment	(28,323)	(26,181)	(32,734)
Proceeds from sale of investments	2,275	0	378
Purchase of investments	(6,748)	(8,245)	(10,938)
Proceeds from sale of business, net of cash disposed	26,193	0	0
Acquisition, net of cash acquired	(1,240,757)	0	0
Proceeds from corporate-owned life insurance	5,065	0	0
Premiums paid for corporate-owned life insurance	(5,065)	(6,000)	0
Net cash used in investing activities	(1,247,322)	(40,316)	(42,909)
Cash flows from financing activities:
Proceeds from revolving line of credit	10,000	20,000	0
Payments of revolving line of credit	(33,000)	(28,000)	(16,000)
Proceeds from term loans	895,000	0	0
Proceeds from convertible senior notes	319,500	0	0
Proceeds from sale of warrants	42,909	0	0
Purchase of convertible note hedge	(72,559)	0	0
Deferred financing costs	(21,760)	0	(30)
Payments of earn-out	0	(215)	0
Payments for employee share-based compensation payroll taxes	(14,190)	(19,413)	(21,490)
Proceeds from exercise of stock options	620	5,277	8,499
Repurchase of common stock	(50,000)	(129,746)	(71,433)
Net cash provided by (used in) financing activities	1,076,520	(152,097)	(100,454)
Net (decrease) increase in cash and cash equivalents	(44,091)	10,710	(24,433)
Cash and cash equivalents at beginning of period	279,601	268,891	293,324
Cash and cash equivalents at end of period	235,510	279,601	268,891
Supplemental disclosure of cash flow information
Interest paid	11,745	4,295	4,880
Income taxes paid	10,364	3,333	8,406
Non-cash items
Capital expenditures in accounts payable	9,390	5,513	2,862
Conversion of note into equity	$ 0	$ 626	$ 0